New drug takes on tough pancreatic cancer

NCT ID NCT05304936

Completed Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called HCW9218 in 21 people with advanced pancreatic cancer that had stopped responding to standard treatments. The drug is designed to boost the immune system and block a protein that helps tumors grow. The main goals were to check safety and find the best dose for future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC CARCINOMA

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
HonorHealth

Scottsdale, Arizona, 85258, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
National Institute of Health/ National Cancer Institute

Bethesda, Maryland, 20892, United States
Washington University in St. Louis

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.